KYBORA is pleased to announce that it has successfully helped its client STADA Arzneimittel AG license Xlucane – a Ranibizumab (Lucentis) biosimilar to Bausch Health.

This latest transaction reinforces KYBORA’s capability in delivering complex cross border transactions working with leading global pharmaceutical companies. “We are seeing an increase in the number of biosimilar deals around the world” said Alan Vanderborght, CEO of KYBORA. “With its global presence, and the depth of its local knowledge, KYBORA is ideally positioned to help companies maximize the value of their assets globally.”

Press release of the deal can be found here:


About the author.


20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

No Comments. Leave a comment  

Leave a Reply

Your email address will not be published. Required fields are marked *